Gilead Sciences Statement on Positive Data Emerging From National Institute of Allergy and Infectious Diseases ’ Study of Investigational Antiviral Remdesivir for COVID-19
FOSTER CITY, Calif.--(BUSINESS WIRE)--Apr. 29, 2020-- Gilead Sciences. Inc. (Nasdaq: GILD) is aware of positive data emerging from the National Institute of Allergy and Infectious Diseases’ (NIAID) study of the investigational...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Allergy | Allergy & Immunology | Clinical Trials | COVID-19 | Infectious Diseases | Pharmaceuticals | Study